Defence Therapeutics Inc.
DTC
Rang in Aktien
#29260
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a... Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Aktienkurs
$0.27889602
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$21.14M
Veränderung (1 Tag)
11.76%
Veränderung (1 Jahr)
-52.35%
Land
CA
Handel Defence Therapeutics Inc. (DTC)
Kategorie
Healthcare
Dividendenrendite-Verlauf für Defence Therapeutics Inc. (DTC)
Dividendenrendite (TTM) von Defence Therapeutics Inc. (Aktienkürzel: DTC) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Defence Therapeutics Inc. (DTC) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
| Jahr | Dividendenrendite | ändert |
|---|---|---|
| Nicht genügend Daten für die angegebenen Daten. | ||
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | Dividendenrendite | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
